Clinical phenotypes and age-related differences in SGLT2 inhibitor-associated ketoacidosis: A nationwide pharmacovigilance case-series study
Aging Clinical and Experimental Research · 17.11.2026
DOI: 10.1007/s40520-026-03566-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Clinical and Experimental Research, online erschienen am 17.11.2026. Verfasst von Nathanaël Bassas Letissier und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
With the expanding use of sodium-glucose cotransporter 2 inhibitors, pharmacovigilance data can help characterize rare but serious adverse drug reactions such as diabetic ketoacidosis.
Aims
To describe the clinical spectrum and age-related differences in sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis and identify distinct clinical presentation patterns using the French Pharmacovigilance Database.
Methods
We conducted a retrospective nationwide case-series study including all expert-adjudicated reports of sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis recorded in the French Pharmacovigilance Database up to December 31, 2025. Clinical characteristics were compared between patients aged < 65 and ≥ 65 years. Unsupervised clustering was used to identify clinical presentation patterns.
Results
Among 299 reports screened, 242 expert-adjudicated cases of ketoacidosis were included (median age 67 years [interquartile range 57–76]; 43% women), of which 88 (36%) fulfilled all three 2024 ADA/EASD diagnostic domains. Euglycemic DKA occurred in 64/165 patients with available blood glucose data (39%), moderate-to-severe metabolic acidosis in 107/177 patients with available pH data (60%), and 100/240 patients with available ICU data (42%) were admitted to an ICU. Three clinical presentation patterns were identified: (1) a fasting-related phenotype characterized by gastrointestinal symptoms and fasting; (2) a perioperative phenotype associated with recent surgery; and (3) an infection-related phenotype characterized by infection, neurological symptoms, and falls, predominantly affecting older patients. Neither moderate-to-severe acidosis nor ICU admission differed significantly between age groups.
Discussion
Sodium-glucose cotransporter 2 inhibitor-associated ketoacidosis shows heterogeneous presentations in routine practice. Older adults more often presented with atypical manifestations, whereas younger patients more often exhibited gastrointestinal symptoms.
Conclusions
In older adults receiving sodium-glucose cotransporter 2 inhibitors, ketoacidosis should be considered when infection, neurological symptoms, or falls occur, even in the absence of gastrointestinal symptoms.
Zitieren
APA
Letissier, N. B., Mirfendereski, N., Laroche, M., Faillie, J., Paccalin, M., Damin-Pernik, M., Fedrizzi, S., Azzouz, B., Largeau, B., Saulnier, P., Allouchery, M., & Mosbah, H. (2026). Clinical phenotypes and age-related differences in SGLT2 inhibitor-associated ketoacidosis: A nationwide pharmacovigilance case-series study. Aging Clinical and Experimental Research. https://doi.org/10.1007/s40520-026-03566-2
Vancouver
Letissier NB, Mirfendereski N, Laroche M, Faillie J, Paccalin M, Damin-Pernik M, et al. Clinical phenotypes and age-related differences in SGLT2 inhibitor-associated ketoacidosis: A nationwide pharmacovigilance case-series study. Aging Clinical and Experimental Research. 2026. doi:10.1007/s40520-026-03566-2
BibTeX
@article{Letissier2026,
author = {Letissier, Nathanaël Bassas and Mirfendereski, Nassir and Laroche, Marie-Laure and Faillie, Jean-Luc and Paccalin, Marc and Damin-Pernik, Marlène and Fedrizzi, Sophie and Azzouz, Brahim and Largeau, Bérenger and Saulnier, Pierre-Jean and Allouchery, Marion and Mosbah, Helena},
title = {Clinical phenotypes and age-related differences in SGLT2 inhibitor-associated ketoacidosis: A nationwide pharmacovigilance case-series study},
journal = {Aging Clinical and Experimental Research},
year = {2026},
doi = {10.1007/s40520-026-03566-2}
}
EUVIMED